Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1297-1304

  Donia, Marco ^a,b   Ellebaek, Eva ^a   Andersen, Mads Hald ^a   Straten, Per Thor ^a   Svane, Inge Marie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

T cells; Adoptive T cell therapy; Melanoma; Tumor infiltrating lymphocytes; V 1 T cells

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; METASTATIC MELANOMA; PATIENT SAFETY; PHYSICAL TOLERANCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VDELTA1 T LYMPHOCYTE;

EID: 84879085212     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21659     Document Type: Article

References (29)

1. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975-1026; PMID:10837080; http://dx.doi.org/10.1146/annurev.immunol.18.1.975.
2. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007; 67:5-8; PMID:17210676; http://dx.doi.org/10.1158/0008-5472.CAN-06-3069.
3. Shimura E, Hozumi N, Kanagawa O, Metzger D, Chambon P, Radtke F, et al. Epidermal gammadelta T cells sense precancerous cellular dysregulation and initiate immune responses. Int Immunol 2010; 22:329-40; PMID:20185432; http://dx.doi.org/10.1093/intimm/dxq014.
4. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999; 96:6879-84; PMID:10359807; http://dx.doi.org/10.1073/pnas.96.12.6879.
5. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279:1737-40; PMID:9497295; http://dx.doi.org/10.1126/science.279.5357.1737.
6. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol 2002; 169:1236-40; PMID:12133944.
7. Zhao J, Huang J, Chen H, Cui L, He W. Vdelta1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem Biophys Res Commun 2006; 339:232-40; PMID:16297874; http://dx.doi.org/10.1016/j.bbrc.2005.10.198.
8. Li J, Cui L, He W. Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA. Cell Mol Immunol 2005; 2:253-8; PMID:16274622.
9. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10:467-78; PMID:20539306; http://dx.doi.org/10.1038/nri2781.
10. Bachelez H, Flageul B, Degos L, Boumsell L, Bensussan A. TCR gamma delta bearing T lymphocytes infiltrating human primary cutaneous melanomas. J Invest Dermatol 1992; 98:369-74; PMID:1532004; http://dx.doi.org/10.1111/1523-1747.ep12499808.
11. Yazdi AS, Morstedt K, Puchta U, Ghoreschi K, Flaig MJ, Rocken M, et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol 2006; 126:393-8; PMID:16374454; http://dx.doi.org/10.1038/sj.jid.5700082.
12. Petrini I, Scatena C, Naccarato AG, Petrini M. CD57 and γδ T-cell receptor expression in nodal metastatic spread of melanoma. Eur J Clin Invest 2012; 42:575-6; PMID:22050593; http://dx.doi.org/10.1111/j.1365-2362.2011.02612.x.
13. Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of "Standard" and "Young" tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol 2011; PMID:21955245.
14. Godoy-Ramirez K, Mäkitalo B, Thorstensson R, Sandström E, Biberfeld G, Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 2005; 68:71-80; PMID:16228974; http://dx.doi.org/10.1002/cyto.a.20189.
15. Roberts AI, Blumberg RS, Christ AD, Brolin RE, Ebert EC. Staphylococcal enterotoxin B induces potent cytotoxic activity by intraepithelial lymphocytes. Immunology 2000; 101:185-90; PMID:11012771; http://dx.doi.org/10.1046/j.1365-2567.2000.00088.x.
16. Hayball JD, Robinson JH, O'Hehir RE, Verhoef A, Lamb JR, Lake RA. Identification of two binding sites in staphylococcal enterotoxin B that confer specificity for TCR V beta gene products. Int Immunol 1994; 6:199-211; PMID:8155597; http://dx.doi.org/10.1093/intimm/6.2.199.
17. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:1066; PMID:2343314.
18. Rust CJ, Koning F. Gamma delta T cell reactivity towards bacterial superantigens. Semin Immunol 1993; 5:41-6; PMID:8467094; http://dx.doi.org/10.1006/smim.1993.1006.
19. Maeurer M, Zitvogel L, Elder E, Storkus WJ, Lotze MT. Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 1995; 14:188-97; PMID:8696008.
20. Stinissen P, Vandevyver C, Raus J, Zhang J. Superantigen reactivity of gamma delta T cell clones isolated from patients with multiple sclerosis and controls. Cell Immunol 1995; 166:227-35; PMID:7497524; http://dx.doi.org/10.1006/cimm.1995.9975.
21. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, et al. Isopentenyl pyrophosphate-activated CD56+ gammadelta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14:4232-40; PMID:18594005; http://dx.doi.org/10.1158/1078-0432.CCR-07-4912.
22. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116.
23. Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother 2010; 33:547-56; PMID:20463593; http://dx.doi.org/10.1097/CJI.0b013e3181d367bd.
24. Urban EM, Li H, Armstrong C, Focaccetti C, Cairo C, Pauza CD. Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells. BMC Immunol 2009; 10:50; PMID:19772585; http://dx.doi.org/10.1186/1471-2172-10-50.
25. Cohavy O, Targan SR. CD56 marks an effector T cell subset in the human intestine. J Immunol 2007; 178:5524-32; PMID:17442934.
26. Casado JG, Soto R, DelaRosa O, Peralbo E, del Carmen Muñoz-Villanueva M, Rioja L, et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother 2005; 54:1162-71; PMID:15889254; http://dx.doi.org/10.1007/s00262-005-0682-5.
27. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000; 164:1148-52; PMID:10640724.
28. Donia M, Hansen M, Sendrup SL, Zeeberg Iversen T, Ellebæk E, Andersen MH, et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-gammma enhances anticancer responses of cell products for infusion. J Invest Dermatol 2012; In press.
29. Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met O, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and lowdose Interleukin-2 in metastatic melanoma patients. J Transl Med 2012;10:169; PMID:22909342; http://dx.doi.org/10.1186/1479-5876-10-169.